How Asciminib Has Impacted the CML Treatment Landscape

Conference|ASH Annual Meeting and Exposition - American Society of Hematology Annual Meeting and Exposition

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses how asciminib has impacted the treatment landscape for chronic myeloid leukemia.

Pharmacy Times interviewed Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, on her presentation at the 63rd American Society of Hematology Annual Meeting & Exposition on new longer-term efficacy and safety data from the pivotal phase 3 ASCEMBL study for FDA-approved asciminib.

During the interview, Mendila discussed how the recent FDA approval of asciminib for chronic myeloid leukemia (CML) has impacted the CML treatment landscape.